- Home
- NMT vs COYA Comparison
NMT vs COYA Comparison
Compare NMT & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- COYA
- Stock Information
- Founded
- NMT 1993
- COYA 2020
- Country
- NMT United States
- COYA United States
- Employees
- NMT N/A
- COYA N/A
- Industry
- NMT Finance/Investors Services
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- COYA Health Care
- Exchange
- NMT Nasdaq
- COYA Nasdaq
- Market Cap
- NMT 110.6M
- COYA 99.8M
- IPO Year
- NMT N/A
- COYA 2022
- Fundamental
- Price
- NMT $11.73
- COYA $5.51
- Analyst Decision
- NMT
- COYA Strong Buy
- Analyst Count
- NMT 0
- COYA 4
- Target Price
- NMT N/A
- COYA $17.00
- AVG Volume (30 Days)
- NMT 19.1K
- COYA 40.7K
- Earning Date
- NMT 01-01-0001
- COYA 08-11-2025
- Dividend Yield
- NMT 3.21%
- COYA N/A
- EPS Growth
- NMT N/A
- COYA N/A
- EPS
- NMT N/A
- COYA N/A
- Revenue
- NMT N/A
- COYA $3,685,107.00
- Revenue This Year
- NMT N/A
- COYA $105.26
- Revenue Next Year
- NMT N/A
- COYA N/A
- P/E Ratio
- NMT N/A
- COYA N/A
- Revenue Growth
- NMT N/A
- COYA N/A
- 52 Week Low
- NMT $9.05
- COYA $4.65
- 52 Week High
- NMT $10.93
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- NMT 36.79
- COYA 45.71
- Support Level
- NMT $11.54
- COYA $5.30
- Resistance Level
- NMT $12.20
- COYA $5.87
- Average True Range (ATR)
- NMT 0.19
- COYA 0.38
- MACD
- NMT -0.06
- COYA -0.01
- Stochastic Oscillator
- NMT 3.03
- COYA 33.96
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.